Supernus Pharma (SUPN) Tops Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Supernus Announces Second Quarter 2021 Financial Results
August 4, 2021 4:10 PM EDTSecond quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020Qelbree launched in the U.S. for pediatric ADHD at the end of May 2021Qelbree sNDA for adult ADHD submitted to the FDASPN-830 (apomorphine infusion pump) NDA resubmission anticipated in the second half of 2021
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system... More
